Biopolym. Cell. 2019; 35(1):39-53.
http://dx.doi.org/10.7124/bc.000995
Genomics, Transcriptomics and Proteomics
Expression of cancer-associated genes in prostate tumors at mRNA and protein levels
1Gerashchenko G. V., 2Grygoruk O. V., 1Rosenberg E. E., 3Bondarenko Yu. M., 4, 5Kashuba E. V., 1, 5Kashuba V. I.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680
  2. Hospital "Boris"
    12A, pr-t Mykoly Bazhana, Kyiv, Ukraine, 02140
  3. State Institution «Institute of Urology of NAMS of Ukraine»
    9-a, Yu. Kotsubyns'koho Str., Kyiv, Ukraine, 04053
  4. R. E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine
    45, Vasilkivska Str., Kyiv, Ukraine, 01022
  5. Karolinska Institutet
    Stockholm SE-171 77, Sweden

Abstract

Aim. To analyze an expression pattern of the cancer-associated genes in prostate tumors at mRNA and protein levels and find putative association between the expression of these genes and the genes, controlling epithelial to mesenchymal cell transition (EMT), the markers of prostate cancer and stromal elements. Methods. Relative expression of genes was assessed by a quantitative PCR in 29 prostate cancer tissue samples (T) of different Gleason score (GS) and tumor stage, 29 paired conventionally normal prostate tissue (CNT) samples and in 14 samples of prostate adenomas (A). Immunohistochemistry (IHC) was used to assess protein expression. Results. We found significant differences (p<0.05) in RE of three genes (FOS, PLAU, EPDR1) between the T, N and A groups. FOS was induced in T and CNT, compared with A whereas PLAU and EPDR1 were decreased. Noteworthy, RE of the five genes (FOS, EFNA5, TAGLN, PLAU and EPDR1) changed significantly, depending on GS (p<0.05) in T, compared to the A and/or CNT groups. Moreover, according to the K-means clustering, RE of the FOS, PLAU and EDPR1 genes varied in the tumor groups, consisting of cancers with different GS. The FOS protein signal was higher in adenocarcinomas, compared to hyperplasia. The same trend was demonstrated by q-PCR. FOS expression increased upon the tumor development i.e. was higher in the tumors at stage 3-4. PLAU expression was decreasing meanwhile, as was shown by q-PCR and IHC. Conclusions. IHC data allowed us to understand the high levels of RE dispersion. Mainly, it is due to the expression in other cell types, and not in the prostate gland cells. For the meaningful clustering, prognosis and also for the creation of specific biomarker panels, these two methods should be adequately merged.
Keywords: prostate tumors, gene expression pattern, prostate cancer-associated genes, IHC analysis
Full text: (PDF, in English)

References

[1] Rosenberg EE, Prudnikova TY, Gerashchenko GV, Grigorieva EV, Kashuba VI. Search for genes – potential markers of aggressiveness and metastasis for human prostate cancer. Biopolym Cell. 2013; 29(6):499–505.
[2] Rosenberg IeE, Herashchenko HV, Kashuba VI. [Comparative analysis of gene expression in normal and cancer human prostate cell lines]. Ukr Biochem J. 2014;86(2):119-28.
[3] Rosenberg EE, Gerashchenko GV, Hryshchenko NV, Mevs LV, Nekrasov KA, Lytvynenko RA, Vitruk YV, Gryzodub OP, Stakhovsky EA, Kashuba VI. Expression of cancer-associated genes in prostate tumors. Exp Oncol. 2017;39(2):131-137.
[4] Paller C, Pu H, Begemann DE, Wade CA, Hensley PJ, Kyprianou N. TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer. Prostate. 2019;79(1):31-43.
[5] Wang H, Song K, Sponseller TL, Danielpour D. Novel function of androgen receptor-associated protein 55/Hic-5 as a negative regulator of Smad3 signaling. J Biol Chem. 2005;280(7):5154-62.
[6] Webber JP, Spary LK, Mason MD, Tabi Z, Brewis IA, Clayton A. Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes. Oncotarget. 2016;7(15):20124-39.
[7] Trabert B, Eldridge RC, Pfeiffer RM, Shiels MS, Kemp TJ, Guillemette C, Hartge P, Sherman ME, Brinton LA, Black A, Chaturvedi AK, Hildesheim A, Berndt SI, Safaeian M, Pinto L, Wentzensen N. Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Int J Cancer. 2017;140(3):600-610.
[8] Liu Q, Russell MR, Shahriari K, Jernigan DL, Lioni MI, Garcia FU, Fatatis A. Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features. Cancer Res. 2013;73(11):3297-305.
[9] Piechaczyk M, Blanchard JM. c-fos proto-oncogene regulation and function. Crit Rev Oncol Hematol. 1994;17(2):93-131. Review.
[10] Alfonso-Gonzalez C, Riesgo-Escovar JR. Fos metamorphoses: Lessons from mutants in model organisms. Mech Dev. 2018;154:73-81.
[11] Uluçkan Ö, Guinea-Viniegra J, Jimenez M, Wagner EF. Signalling in inflammatory skin disease by AP-1 (Fos/Jun). Clin Exp Rheumatol. 2015;33(4 Suppl 92):S44-9.
[12] Bakiri L, Hamacher R, Graña O, Guío-Carrión A, Campos-Olivas R, Martinez L, Dienes HP, Thomsen MK, Hasenfuss SC, Wagner EF. Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation. J Exp Med. 2017;214(5):1387-1409.
[13] Hao Y, Zhu L, Yan L, Liu J, Liu D, Gao N, Tan M, Gao S, Lin B. c-Fos mediates α1, 2-fucosyltransferase 1 and Lewis y expression in response to TGF-β1 in ovarian cancer. Oncol Rep. 2017;38(6):3355-3366.
[14] Shankar E, Song K, Corum SL, Bane KL, Wang H, Kao HY, Danielpour D. A Signaling Network Controlling Androgenic Repression of c-Fos Protein in Prostate Adenocarcinoma Cells. J Biol Chem. 2016;291(11):5512-26. PubMed Central
[15] Sharma NV, Pellegrini KL, Ouellet V, Giuste FO, Ramalingam S, Watanabe K, Adam-Granger E, Fossouo L, You S, Freeman MR, Vertino P, Conneely K, Osunkoya AO, Trudel D, Mes-Masson AM, Petros JA, Saad F, Moreno CS. Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer. Cancers (Basel). 2018;10(10). pii: E379.
[16] Le Bras GF, Taubenslag KJ, Andl CD. The regulation of cell-cell adhesion during epithelial-mesenchymal transition, motility and tumor progression. Cell Adh Migr. 2012;6(4):365-73.
[17] Huang CY, Chang MC, Huang WY, Huang CT, Tang YC, Huang HD, Kuo KT, Chen CA, Cheng WF. Urokinase-type plasminogen activator resulting from endometrial carcinogenesis enhances tumor invasion and correlates with poor outcome of endometrial carcinoma patients. Sci Rep. 2015;5:10680.
[18] BBanyard J, Chung I, Migliozzi M, Phan DT, Wilson AM, Zetter BR, Bielenberg DR. Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer. BMC Cancer. 2014;14:387.
[19] Gerashchenko GV, Mevs LV, Chashchina LI, Pikul MV, Gryzodub OP, Stakhovsky EO, Kashuba VI. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion. Exp Oncol. 2018;40(2):101-108.
[20] Gerashchenko GV, Rynditch AV, Kashuba VI. Molecular profiling of prostate tumors. Dopov Nac Acad Nauk Ukr. 2018; 6: 113-9.
[21] Gerashchenko GV, Mankovska OS, Dmitriev AA, Mevs LV, Rosenberg EE, Pikul MV, Marynychenko MV, Gryzodub OP, Stakhovsky EO, Kashuba VI. Expression of epithelial-mesenchymal transition-related genes in prostate tumours. Biopolym Cell. 2017; 33(5):335–55.
[22] Mevs LV, Gerashchenko GV, Rosenberg EE, Pikul MV, Marynychenko MV, Gryzodub OP, Vozianov SO, Stakhovsky EA, Kashuba VI. Detection of prostate specific ETS fusion transcripts in cancer samples. Biopolym Cell. 2017; 33(4):256-67.
[23] Schmidt U, Fuessel S, Koch R, Baretton GB, Lohse A, Tomasetti S, Unversucht S, Froehner M, Wirth MP, Meye A. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate. 2006;66(14):1521-34.
[24] Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995; 57(1): 289-300.